In BENCHMRK-1 study at 48 weeks, Isentress plus optimized background therapy (OBT) maintained suppression of HIV RNA levels below 400 copies/mL in 74% of patients (170 out of 231) compared to 36% of patients (43 out of 118) receiving placebo plus OBT; p<0.001. In the companion study, BENCHMRK-2, Isentress plus OBT suppressed viral loads below 400 copies/mL in 71% of patients (162 out of 228) compared to 38% of patients (45 out of 119) receiving placebo plus OBT; p<0.001. In addition, in BENCHMRK-1, after 48 weeks of therapy, ISENTRESS plus OBT suppressed viral load to below 50 copies/mL in 65% of patients (149 out of 231) compared to 31% of patients (37 out of 118) who received placebo plus OBT; p<0.001. Isentress plus OBT increased CD4 cell counts from baseline by 120 cells/mm3 compared to 49 cells/mm3 for patients receiving placebo plus OBT; p<0.001.In BENCHMRK-2 after 48 weeks, 60% of patients (136 out of 228) receiving Isentress plus OBT achieved viral loads below 50 copies/mL compared to 34% of patients (41 out of 119) receiving placebo plus OBT; p<0.001. The multi-center, double-blind, randomized, placebo-controlled Phase III studies (BENCHMRK-1 and BENCHMRK-2) compared Isentress in combination with OBT to placebo plus OBT. The primary endpoint of this ongoing study is the percentage of patients in each study arm that achieve HIV RNA viral levels less than 400 copies/mL at Week 16. Patients received Isentress 400mg or placebo, each dosed orally twice daily in combination with OBT. OBT was determined based on patients's prior treatment history and results from HIV resistance testing.